I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population
- Written by PR Newswire
![]() |
More than 100 million people in the US have this HLA-A haplotype
PALO ALTO, Calif., Oct. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the company has successfully generated iPS cell lines that are...
Read more: I Peace announces new iPSC lines to reduce immune rejection risk for U.S. population















